---
schema_version: "secwatch.filing_event.v1"
accession: "0001048477-25-000049"
form_type: "8-K"
ticker: "BMRN"
cik: "0001048477"
company_name: "BIOMARIN PHARMACEUTICAL INC"
filed_at: "2025-05-01T23:59:59+00:00"
generated_at: "2026-05-22T23:38:50.594847+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# BioMarin Q1 2025 revenue $745M (+15% YoY), GAAP EPS $0.95, reaffirms 2025 guidance

## Summary
- Q1 total revenues $745M (+15% Y/Y); GAAP net income $186M (+109% Y/Y); non-GAAP income $221M (+58% Y/Y).
- VOXZOGO revenue $214M (+40% Y/Y) driven by global demand; Enzyme Therapies revenue $484M (+8% Y/Y) led by PALYNZIQ (+22% Y/Y).
- GAAP diluted EPS $0.95 (+107% Y/Y); non-GAAP diluted EPS $1.13 (+59% Y/Y). Operating margin expanded 16.4 ppt GAAP, 11.9 ppt non-GAAP.
- Reaffirmed full-year 2025 financial guidance; notes immaterial tariff exposure from enacted tariffs.
- Pipeline: VOXZOGO pivotal hypochondroplasia study fully enrolled; BMN 333 plan agreed with FDA; PALYNZIQ adolescent study met primary endpoint.

## SEC filing metadata
- accession: 0001048477-25-000049
- form_type: 8-K
- ticker: BMRN
- cik: 0001048477
- company_name: BIOMARIN PHARMACEUTICAL INC
- filed_at: 2025-05-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1048477/000104847725000049/0001048477-25-000049-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1048477/000104847725000049/bmrn-20250501.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001048477-25-000049
- JSON: https://secwatch.observer/filing/0001048477-25-000049.json
- Plain text: https://secwatch.observer/filing/0001048477-25-000049.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.